Lucid Group Inc vs Revvity Inc — how do they compare? Lucid Group Inc trades at $7.02 (market cap $2.77B), while Revvity Inc trades at $110.22 (market cap $11.87B). The key difference: Revvity Inc is far larger — about 4.3× Lucid Group Inc's market cap, and Revvity Inc pays a 0.26% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| LCID | RVTY | |
|---|---|---|
Market Cap | $2.77B | $11.87B |
Sector | Consumer Cyclical | Technology |
52-Week High | $31.30 | $117.75 |
52-Week Low | $4.62 | $82.26 |
Enterprise Value | $5.24B | $14.36B |
Dividend Yield | — | 0.26% |
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $7.33, down 0.41% on the day, amid mixed technical signals and severe fundamental challenges. The stock shows a bullish moving average trend but bearish oscillators, with RSI at 70.77 suggesting overbought conditions. Financially, the company reported a net loss of $2.70 billion on $1.35 billion revenue in 2025, with negative margins across gross profit (-95.6%) and net income (-239.81%). Recent news highlights class-action lawsuits and bankruptcy rumors, though management denies financial distress.
The outlook remains highly speculative with significant execution and liquidity risks. Analyst consensus is cautious, with 66.7% hold ratings and a $10.50 price target implying limited upside. Investment appeal hinges on Lucid's ability to achieve profitability and scale production, but current financials and legal overhangs present substantial headwinds for near-term performance.
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
Trailing returns across standard periods
Latest headlines on both assets
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →